Kamada (KMDA) Q4 2025 earnings review
Record Year Masked by a Q4 Profitability Reversal and Major Pipeline Failure
Kamada achieved its full-year guidance with 12% revenue growth, but the Q4 results paint a sobering picture of deteriorating earnings quality. While Q4 sales grew 15% YoY to $44.7M, the bottom line contracted: Net Income fell 6.5% and Adjusted EBITDA dropped 11%. A negative product mix shift crushed gross margins to 38% (down from 44% a year ago). More fundamentally, management quietly discontinued the Phase 3 Inhaled AAT clinical trial—previously touted as the company's fourth strategic growth pillar. Despite initiating a new dividend policy and projecting 13% revenue growth for 2026, the Q4 margin collapse and pipeline failure introduce significant execution risk.
🐂 Bull Case
The Proprietary products segment remains robust, accelerating to 22% YoY growth in Q4. Consistent international sales of GLASSIA and KAMRAB are driving steady, double-digit top-line expansion.
Management declared a $0.25 per share dividend (~$14.4M total payout). Committing to distribute at least 50% of annual net income signals strong confidence in underlying cash generation.
🐻 Bear Case
Gross margins plummeted from ~45% in H1'25 to 38% in Q4. If this unfavorable sales mix shift persists, the ambitious 2026 Adjusted EBITDA targets will be mathematically impossible to hit.
The discontinuation of the InnovAATe Phase 3 trial permanently removes Kamada's most significant long-term upside catalyst, increasing the urgency—and pressure—on finding accretive M&A.
⚖️ Verdict: ⚪
Neutral. The base business continues to scale revenues and generate cash, validated by the new dividend. However, a major pipeline failure, an unexpected Q4 margin contraction, and a shrinking distribution segment cap near-term enthusiasm.
Key Themes
The Quiet Death of a Core Pillar (Inhaled AAT)
In previous quarters, management aggressively pitched the pivotal Phase 3 InnovAATe trial for inhaled Alpha-1 Antitrypsin (AAT) therapy as one of the company's four primary growth pillars. In the Q4 release, it was quietly relegated to a single bullet point: 'Announced discontinuation of the Company's Phase 3 Inhaled AAT clinical trial.' This is a massive failure of a long-term innovation bet, eliminating what was supposed to be a major entry into a $1.4B market.
Distribution Segment Reverses Course
Narrative contradiction: Management continues to claim 'overall increased sales in the Distribution segment through the launch of biosimilar.' The data tells a different story. After surging +90% in Q2 and +62% in Q3, Distribution revenue collapsed in Q4, falling 15% YoY to $6.4M. If biosimilar launches are truly gaining traction, this abrupt deceleration requires immediate explanation.
Q4 Margin Compression
Profitability broke trend in Q4. Gross margins collapsed to 38% (down from 44% in 24Q4 and 42% in 25Q3). Adjusted EBITDA margin fell sequentially to 17% from 25% in Q3. Management blamed a 'change in product and markets sales mix.' This indicates that Q4's revenue beat was driven entirely by low-margin volume, punishing the bottom line.
Proprietary Portfolio Anchoring Growth
The core Proprietary segment remains the engine of the company, accelerating to 22% YoY growth ($38.2M) in Q4. Growth was primarily fueled by VARIZIG and KEDRAB in the U.S. and GLASSIA in ex-U.S. markets, proving that the established specialty plasma portfolio has durable demand.
Dividend Policy Initiation
Kamada adopted a formal policy to distribute at least 50% of annual net income as dividends, starting with a $0.25 per share payout. This is a strong signal of financial maturity and reflects management's confidence that their $75M cash pile and ongoing operating cash flow can fund both M&A and shareholder returns simultaneously.
Vertical Integration via Plasma Centers
The company's three U.S. plasma collection centers (Beaumont, Houston, San Antonio) are ramping up. With Houston now FDA-approved and San Antonio operational, Kamada is building a vital hedge against third-party specialty plasma costs while creating a new revenue stream from normal source plasma sales.
Canadian Tender Hedges Macro Risks
Kamada secured a $10M-$14M extension from Canadian Blood Services for four specialty products (WINRHO, HEPAGAM, CYTOGAM, VARIZIG) through Q1-28. In an environment where management previously cited global tariffs as a potential macro risk, locking in steady international government contracts provides crucial revenue visibility.
CYTOGAM Clinical Innovation Pivot
With the Inhaled AAT trial dead, Kamada's R&D narrative relies entirely on the CYTOGAM SHIELD studies. This 10-study post-marketing program is attempting to generate fresh data to alter long-stagnant CMV treatment guidelines. It is a slow, multi-year process, but it is now the company's primary organic clinical catalyst.
Other KPIs
Decelerating significantly from $47.6M in FY24. The drop is entirely tied to working capital changes (inventory build and accounts receivable timing), as net income actually grew 40% YoY. The company's liquidity remains highly secure with $75.5M in cash.
Stable YoY (up just 0.6% from $49.9M in 2024). The composition changed: R&D expenses declined by $2.2M due to the discontinuation of the Inhaled AAT study, which was offset by a $3.0M increase in G&A to support commercial operations.
Guidance
Stable. The midpoint of $202.5M implies 12.2% YoY growth, effectively matching the 12.1% growth achieved in FY25. This shows management believes the core commercial portfolio can sustain its current trajectory entirely through organic sales.
Accelerating. The midpoint of $51.5M implies 22.6% YoY growth. This target aggressively contradicts the Q4 margin collapse. To achieve this, Kamada must reverse the negative product mix shift seen in Q4 and strictly hold the line on operating expenses.
Key Questions
Distribution Segment Collapse
Distribution revenue fell 15% YoY in Q4 after massive growth in Q2 and Q3. Is this a permanent correction due to initial channel stocking of the new biosimilars, and does it impact your $15-$20M 5-year target for this segment?
Q4 Margin Reversal
Gross margin dropped sharply to 38% in Q4 from the mid-40s. What specific product mix caused this, and what gives you confidence in modeling 23% Adjusted EBITDA growth for 2026 given this Q4 headwind?
Inhaled AAT Discontinuation
With the Phase 3 InnovAATe trial officially discontinued, how much annual R&D spend will be freed up, and does the loss of this asset accelerate your timeline for executing an M&A transaction to fill the pipeline void?